Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1600 1635 1637 1658 1674
This examiner grants 71% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17927485 | COMPOSITIONS AND METHODS FOR TRANSDIFFERENTIATING CELLS | Non-Final OA | The Regents of the University of California |
| 17604375 | EXOSOME MIMICKING NANOVESICLES MAKING AND BIOLOGICAL USE | Final Rejection | The Regents of the University of California |
| 17786932 | METHODS FOR TREATING HUNTINGTON'S DISEASE | Final Rejection | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL |
| 18015108 | NUTRITIONAL COMPOSITION COMPRISING MIR-3184 | Non-Final OA | SOCIETE DES PRODUITS NESTLE S.A. |
| 19051528 | BIOMARKER miR-32533 FOR COGNITIVE IMPAIRMENT-RELATED DISEASE AND USE THEREOF | Final Rejection | INSTITUTE OF MEDICINAL BIOTECHNOLOGY, CAMS & PUMC |
| 18234690 | RNA-TRIGGERED PROTEIN CLEAVAGE AND APPLICATIONS BY THE CRISPR CAS7-11-CSX29 COMPLEX | Non-Final OA | The University of Tokyo |
| 18008903 | RNA MOLECULE, CHIMERIC NA MOLECULE, DOUBLE-STRANDED RNA MOLECULE, AND DOUBLE-STRANDED CHIMERIC NA MOLECULE | Non-Final OA | THE UNIVERSITY OF TOKYO |
| 17758480 | COMPOSISTIONS AND METHODS FOR CRISPR ENABLED DNA SYNTHESIS | Final Rejection | Duke University |
| 18031495 | NANO-IN-MICRO ENCAPSULATED siRNA DRY POWDER, METHOD FOR PRODUCING THE SAME AND USE OF A POWDER FORMULATION | Non-Final OA | THE UNIVERSITY OF BRITISH COLUMBIA |
| 17934799 | HIGH PURITY gRNA SYNTHESIS PROCESS | Final Rejection | CRISPR Therapeutics AG |
| 18036992 | RIBONUCLEIC ACID PURIFICATION | Non-Final OA | ModernaTX, Inc. |
| 17914662 | COMPOSITIONS AND METHODS FOR TREATING OR AMELIORATING INFECTIONS | Non-Final OA | San Diego State University (SDSU) Foundation, dba San Diego State University Research Foundation |
| 18349989 | NOVEL COMPOSITIONS BASED ON POLYINOSINIC-POLYCYTIDYLIC ACID | Non-Final OA | HIGHLIGHT THERAPEUTICS, S.L. |
| 18266034 | SUBSTANCES AND METHODS FOR TREATING DYSTROPHIC EPIDERMOLYSIS BULLOSA | Non-Final OA | UNIVERSITE DE VERSAILLES ST QUENTIN EN YVELINES |
| 18039858 | ENGINEERED CLASS 2 TYPE V CRISPR SYSTEMS | Non-Final OA | Scribe Therapeutics Inc. |
| 17653221 | METHOD OF TREATING CANCER | Non-Final OA | TARGIMMUNE THERAPEUTICS AG |
| 18001082 | COMPOSITIONS AND METHODS FOR DELIVERING POLYNUCLEOTIDES | Non-Final OA | NeOnc Technologies, Inc. |
| 18035300 | Agent for Regulating Expression and/or Function of RPS25 Gene | Non-Final OA | Luxna Biotech Co., Ltd. |
| 18178242 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS | Non-Final OA | Arrowhead Pharmaceuticals, Inc. |
| 17415759 | DRUG CONJUGATE | Non-Final OA | Sapreme Technologies B.V. |
| 18025589 | SIRNA SEQUENCE FOR EFFECTIVELY INHIBITING EXPRESSION OF EPIDERMAL GROWTH FACTOR RECEPTOR | Non-Final OA | JENKEM TECHNOLOGY CO., LTD. (BEIJING) |
| 18014906 | METHODS AND COMPOSITIONS FOR TREATING EPILEPSY | Non-Final OA | UNIQURE FRANCE |
| 17925807 | ORTHOGONALLY LINKED MULTIMERIC OLIGONUCLEOTIDES | Non-Final OA | MPEG LA, L.L.C. |
| 17638644 | COMPOSITIONS FOR TRANSFER OF CARGO TO CELLS | Final Rejection | Sixfold Bioscience Ltd. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy